Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Jennifer E. Vaughn et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory MyelofibrosisJohn Mascarenhas, Maciej Kaźmierczak, Zübeyde Nur Özkurt et al.|Blood|2024Cited by 15
CML and the WHO: Why?Ellin Berman, Brian Druker, B. Douglas Smith et al.|Journal of Clinical Oncology|2023Cited by 14